<DOC>
	<DOCNO>NCT00247208</DOCNO>
	<brief_summary>The main purpose study determine whether implantation paclitaxel-eluting stent ( Taxus™ ) saphenous vein graft lesion reduce incidence in-stent restenosis 12 month compare similar bare metal stent .</brief_summary>
	<brief_title>The SOS ( Stenting Of Saphenous Vein Grafts ) Trial</brief_title>
	<detailed_description>Introduction : The prevalence coronary artery bypass graft ( CABG ) surgery high veteran population . Saphenous vein use conduit majority CABG operation . Compared arterial conduit , saphenous vein graft ( SVGs ) high rate failure , require percutaneous coronary intervention ( PCI ) repeat CABG . Bare metal stent currently use majority PCI SVGs increase procedural success rate decrease restenosis . However , even use bare metal stent , restenosis still occur 37-53 % SVGs , often require repeat target vein graft revascularization . Drug-eluting stent ( DES ) major breakthrough percutaneous coronary intervention significantly reduce incidence in-stent restenosis de novo lesion native coronary artery . Even though , randomize control trial compare DES bare stent SVG intervention , DES increasingly use label setting , base registry data . DES expensive may provide benefit SVGs since atherosclerotic process different SVGs native coronary artery . We propose compare 12-month angiographic restenosis rate implantation polymer-based paclitaxel-eluting stent Express-2 bare metal stent ( identical paclitaxel-eluting stent drug coating ) saphenous vein graft lesion . Hypothesis : Compared implantation bare metal stent , implantation similar paclitaxel-eluting stent ( Taxus™ , Boston Scientific , Nattick , Massachusetts ) saphenous vein graft lesion reduce incidence angiographic in-stent restenosis 12 month . Specific objective : We propose randomize patient undergo stenting saphenous vein graft lesion bare metal stent identical paclitaxel-eluting stent ( Taxus™ ) order determine : 1. whether paclitaxel-eluting stent reduce incidence binary angiographic in-stent restenosis , assess 12-month follow-up quantitative coronary angiography ( primary study endpoint ) , 2. whether paclitaxel-eluting stent reduce 24-month incidence ischemia-driven target vessel revascularization , target vessel failure , overall major adverse cardiac cerebrovascular event , intra-stent intimal hyperplasia accumulation , measure intravascular ultrasound ( secondary endpoint ) .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>least one 5099 % denovo restenotic lesion saphenous vein graft 2.5 4.0 mm diameter , require percutaneous coronary intervention accord opinion attend cardiologist willing return repeat coronary angiography 12 month able give inform consent previous plan use intravascular brachytherapy target vessel leave ventricular ejection fraction le 25 percent hemorrhagic diatheses contraindication allergy aspirin , thienopyridines , paclitaxel , stainless steel history anaphylaxis response iodinate contrast medium use paclitaxel within 12 month study entry current use colchicine serum creatinine level 2.0 mg per deciliter ( 177 µmol per liter ) leukocyte count less 3500 per cubic millimeter , platelet count le 100,000 per cubic millimeter recent positive pregnancy test , breastfeeding , possibility future pregnancy coexist condition limit life expectancy le 24 month could affect patient 's compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Coronary artery bypass</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty , Transluminal , Percutaneous Coronary</keyword>
	<keyword>Coronary Restenosis</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>